CDXC ChromaDex Corp

Price (delayed)

$1.64

Market cap

$112.08M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.4

Enterprise value

$116.62M

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create ...

Highlights
The gross profit has increased by 11% year-on-year
The revenue has grown by 11% YoY
ChromaDex's debt has increased by 29% YoY but it has decreased by 2.6% from the previous quarter
CDXC's quick ratio has dropped by 91% year-on-year and by 84% since the previous quarter
The equity has dropped by 51% year-on-year and by 20% since the previous quarter

Key stats

What are the main financial stats of CDXC
Market
Shares outstanding
68.34M
Market cap
$112.08M
Enterprise value
$116.62M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.39
Price to sales (P/S)
1.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.69
Earnings
Revenue
$69.06M
EBIT
-$28.28M
EBITDA
-$26.49M
Free cash flow
-$22.1M
Per share
EPS
-$0.4
Free cash flow per share
-$0.32
Book value per share
$0.3
Revenue per share
$1.01
TBVPS
$0.67
Balance sheet
Total assets
$46.61M
Total liabilities
$25.84M
Debt
$4.54M
Equity
$20.78M
Working capital
$20.78M
Liquidity
Debt to equity
0.22
Current ratio
2.17
Quick ratio
0.24
Net debt/EBITDA
-0.17
Margins
EBITDA margin
-38.4%
Gross margin
60.8%
Net margin
-41%
Operating margin
-40.9%
Efficiency
Return on assets
-52%
Return on equity
-99.5%
Return on invested capital
-106.8%
Return on capital employed
-97.9%
Return on sales
-40.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CDXC stock price

How has the ChromaDex stock price performed over time
Intraday
-1.8%
1 week
-20.39%
1 month
-8.38%
1 year
-79.29%
YTD
-56.15%
QTD
-1.8%

Financial performance

How have ChromaDex's revenue and profit performed over time
Revenue
$69.06M
Gross profit
$42.02M
Operating income
-$28.28M
Net income
-$28.32M
Gross margin
60.8%
Net margin
-41%
The company's net income fell by 22% YoY and by 3% QoQ
ChromaDex's operating income has decreased by 22% YoY and by 3% QoQ
The gross profit has increased by 11% year-on-year
The revenue has grown by 11% YoY

Growth

What is ChromaDex's growth rate over time

Valuation

What is ChromaDex stock price valuation
P/E
N/A
P/B
5.39
P/S
1.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.69
The company's EPS fell by 8% YoY and by 2.6% QoQ
The equity has dropped by 51% year-on-year and by 20% since the previous quarter
CDXC's price to book (P/B) is 46% lower than its 5-year quarterly average of 10.1 and 31% lower than its last 4 quarters average of 8.0
CDXC's price to sales (P/S) is 75% lower than its 5-year quarterly average of 6.6 and 54% lower than its last 4 quarters average of 3.6
The revenue has grown by 11% YoY

Efficiency

How efficient is ChromaDex business performance
CDXC's return on invested capital has surged by 61% year-on-year and by 16% since the previous quarter
The company's return on equity fell by 30% YoY and by 22% QoQ
ChromaDex's return on assets has decreased by 18% YoY and by 12% QoQ
The company's return on sales fell by 9% YoY and by 4.3% QoQ

Dividends

What is CDXC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDXC.

Financial health

How did ChromaDex financials performed over time
The total assets is 80% more than the total liabilities
CDXC's quick ratio has dropped by 91% year-on-year and by 84% since the previous quarter
The current ratio has declined by 39% year-on-year and by 9% since the previous quarter
ChromaDex's debt is 78% less than its equity
CDXC's debt to equity has surged by 175% year-on-year and by 22% since the previous quarter
The equity has dropped by 51% year-on-year and by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.